Trial Profile

An Open, Single Arm and Early Clinical Study of TAEST16001 in the Treatment of Solid Tumor Mainly Containing Soft Tissue Sarcoma With Positive Expression of Tumor Antigen NY-ESO-1 (HLA-A * 02:01)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TAEST 16001 (Primary) ; Interleukin-2
Indications Advanced breast cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Soft tissue sarcoma; Solid tumours
Focus Adverse reactions
Acronyms HLA-A * 02:01

Most Recent Events

11 Apr 2023 Planned End Date changed from 1 Mar 2023 to 1 May 2024.
13 Dec 2022 Status changed from recruiting to active, no longer recruiting.
14 Sep 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Nov 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com